natgillin/translations-raw huggingface dataset:
The proportion of patients experiencing adverse events (AE) was similar in the patients aged 65 years and those aged 65 years.
Kõrvaltoimetega patsientide osakaal oli sarnane alla 65-aastaste ning 65-aastaste ja vanemate patsientide seas.
The proportion of patients experiencing AEs was similar in those aged <65 years and those aged ≥65 years in both studies.
Kõrvaltoimete esinemise osakaal oli mõlemas uuringus sarnane < 65-aastaste ja ≥ 65-aastaste seas. ≥ 65-aastastel patsientidel tekkisid võrreldes
The proportion of patients experiencing AEs was similar in those aged <65 years and those aged ≥65 years in both studies.
Kõrvaltoimete esinemise osakaal oli mõlemas uuringus sarnane <65-aastaste ja ≥65-aastaste seas. ≥65-aastastel patsientidel tekkisid võrreldes
The proportion of patients healed after treatment with InductOs 1.5 mg/ml was significantly higher at all visits from 10 weeks to 12 months post-operative, suggesting accelerated fracture healing.
InductOs’t annuses 1,5 mg/ml saanud patsientide rühmas oli murdude paranemise määr kõrgem kõigil visiitidel alates 10 nädalast kuni 12 kuuni postoperatiivselt, mis näitas murru paranemise kiirenemist.
The proportion of patients losing 10% or more of their body weight was 20% in the patients taking this dose of Xenical and 8% in those taking placebo.
Patsientide osakaal, kelle kehakaal vähenes vähemalt 10%, oli kõnealuses annuses Xenicali võtnud patsientide rühmas 20% ning platseebot võtnud patsientide rühmas 8%.
The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.
Patsientide proportsioon, keda raviti Enbreliga ning kellel tekkisid kardiolipiinivastased antikehad, suurenes sarnaselt platseeboga ravitud patsientidele.
The proportion of patients treated with etanercept who developed anticardiolipin antibodies was similarly increased compared to placebo- treated patients.
Patsientide osakaal, keda raviti etanertseptiga ning kellel tekkisid kardiolipiinivastased antikehad, suurenes sarnaselt platseeboga ravitud patsientidele.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Uuringute I…IX, CLASSIC 1, GAIN ja CHARM kontrollitud topeltpimefaasis katkestas kõrvaltoimete tõttu ravi 5,7% Trudexa ja 5,3% kontrollgrupi patsientidest.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Uuringute I…IX, CLASSIC I, GAIN ja CHARM kontrollitud topeltpimefaasis katkestas kõrvaltoimete tõttu ravi 5, 7% Trudexa ja 5,3% kontrollgrupi patsientidest.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I−IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients.
Uuringute I…IX, CLASSIC I, GAIN ja CHARM kontrollitud topeltpimefaasis katkestas kõrvaltoimete tõttu ravi 5,7% Trudexa ja 5,3% kontrollgrupi patsientidest.
The proportion of patients who discontinued treatment due to adverse events was 9% for vedolizumab-treated patients and 10% for placebo-treated patients.
Kõrvaltoimete tõttu ravi katkestanud patsientide osakaal oli 9% vedolizumabiga ravitud patsientidest ja 10% platseeboga ravitud patsientidest.
The proportion of patients who discontinued treatment due to adverse reactions was 7% for both Benlysta-treated and placebo-treated patients.
Kõrvaltoimete tõttu ravi katkestanud patsientide osakaal oli nii Benlysta’ga ravitud kui platseebot saanud patsientide seas 7%.
The proportion of patients who discontinued treatment due to ARs was 3.3% for abatacept- treated patients and 2.0% for placebo-treated patients.
Patsientide osakaal, kes KT tõttu katkestasid ravi oli 3,3% abatatsepti ja 2,0% platseebot saanute rühmas.
The proportion of patients who had both a reduction in weight and HbA1c ranged from 70 to 79 % (the proportion of patients who had a reduction of HbA1c ranged from 88 to 96 %).
Patsientide hulk, kellel esines nii kehakaalu kui HbA1c langus, oli umbes 70–79 % (ainult HbA1c langusega patsientide hulk oli 88–96 %).
The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Enviage and placebo, respectively.
Patsientide hulk, kellel albumiini ja kreatiniini suhe uriinis vähenes algpunktist lõpp-punktini vähemalt 50%’i võrra, oli Enviage korral 24,7% ja platseebo korral 12,5%.
The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Tekturna and placebo, respectively.
Patsientide hulk, kellel albumiini ja kreatiniini suhe uriinis vähenes algpunktist lõpp-punktini vähemalt 50%’i võrra, oli Tekturna korral 24,7% ja platseebo korral 12,5%.
The proportion of patients who had undetectable levels of HIV in their blood was about 45% when Celsentri was added to optimised background therapy compared with 23% of the patients receiving optimised background therapy only.
Celsentri lisamisel optimeeritud foonravile oli patsientide osakaal, kellel HIV-taset veres ei avastatud, ligikaudu 45%, võrreldes 23%-ga patsientidest, kes said ainult optimeeritud foonravi.
The proportion of patients who permanently discontinued treatment due to adverse events was 0.2% and the proportion of patients who experienced any severe adverse events was 3.2% for patients receiving Epclusa for 12 weeks.
0,2% patsientidest lõpetas ravi kõrvaltoimete tõttu ning 3,2%-l 12 nädala vältel Epclusat saanud patsientidest tekkis mõni raske kõrvaltoime.
The proportion of patients who progressed to cancer in the PhotoBarr PDT + OM group was statistically lower than in the OM only group (p=0.0060).
Patsientide osakaal, kellel arenes vähk, oli PhotoBarr’i PDT+OM grupis statistiliselt olulisel määral madalam kui ainult OM-i grupis (p=0,0060).
The proportion of patients who received Quinsair throughout Study 209 Core and Extension Phases (with a highest levofloxacin MIC P. aeruginosa isolate exceeding 1 µg/ml) was similar at the end of treatment during Cycles 1 and 3 in the Core Phase (76.6% to 83.3%) and at the end of treatment during Cycles 4 to 6 in the Extension Phase (77.8% to 87.5%).
Patsientide osakaal, kes said uuringu 209 põhi- ja jätkufaaside ajal Quinsair’i kõrgeima levofloksatsiini MIC P. aeruginosa isolaadiga (üle 1 µg/ml), oli põhifaasi 1 ja 3. tsükli lõppedes (76,6...83,3%) ning jätkufaasi 4 ja 6. tsükli lõppedes (77,8...87,5%) sarnane.
The proportion of patients who responded to treatment was therefore similar in the two groups, but when only the damage to the cornea was considered, Ikervis was significantly better than the vehicle at reducing it.
Seega oli nende patsientide osakaal, kellel tekkis ravivastus, kahes rühmas sarnane, kuid kui vaadeldi ainult sarvkestakahjustust, oli Ikervis selle vähendamisel oluliselt parem kui vehiikel.
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 12 was greater for Incruse 55 micrograms (44%) compared with placebo (26%) in the 12-week study.
12-nädalases uuringus oli patsientide protsent, kes saavutasid 12. nädalal vähemalt minimaalse kliiniliselt olulise SGRQ skoori erinevuse (MCID) (määratleti kui vähenemist 4 ühiku võrra ravieelsest väärtusest), suurem Incruse 55 mikrogrammi (44%) kui platseebo puhul (26%).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for ANORO (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).
Patsientide protsent, kes saavutasid 24. nädalal vähemalt minimaalse kliiniliselt olulise SGRQ skoori erinevuse (MCID) (määratleti kui vähenemist 4 ühiku võrra ravieelsega võrreldes), oli suurem ANORO puhul (49%) võrreldes platseebo (34%) ja mõlema monoteraapia komponendiga (44% umeklidiiniumi ja 48% vilanterooli puhul).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for LAVENTAIR (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).
Patsientide protsent, kes saavutasid 24. nädalal vähemalt minimaalse kliiniliselt olulise SGRQ skoori erinevuse (MCID) (määratleti kui vähenemist 4 ühiku võrra ravieelsega võrreldes), oli suurem LAVENTAIR’i puhul (49%) võrreldes platseebo (34%) ja mõlema monoteraapia komponendiga (44% umeklidiiniumi ja 48% vilanterooli puhul).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 12 was greater for Incruse (38%) compared with placebo (15%) in the 12- week study.
12-nädalases uuringus oli patsientide protsent, kes saavutasid 12. nädalal vähemalt minimaalse kliiniliselt olulise TDI skoori erinevuse (MCID) 1 ühiku võrra, suurem Incruse (38%) kui platseebo puhul (15%).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for ANORO (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Patsientide protsent, kes saavutasid 24. nädalal vähemalt minimaalse kliiniliselt olulise TDI skoori erinevuse (MCID) 1 ühiku võrra, oli suurem ANORO puhul (58%) võrreldes platseebo (41%) ja mõlema monoteraapia komponendiga (53% umeklidiiniumi ja 51% vilanterooli puhul).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for LAVENTAIR (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Patsientide protsent, kes saavutasid 24. nädalal vähemalt minimaalse kliiniliselt olulise TDI skoori erinevuse (MCID) 1 ühiku võrra, oli suurem LAVENTAIR’i puhul (58%) võrreldes platseebo (41%) ja mõlema monoteraapia komponendiga (53% umeklidiiniumi ja 51% vilanterooli puhul).
The proportion of patients who stopped treatment because their pain was not controlled was lower in patients treated with Ionsys (and ranged between 8% and 27%) than in those treated with placebo (where it ranged between 40 and 57%).
Patsientide osakaal, kes katkestasid ravi ebapiisava valuvaigistuse tõttu, oli Ionsysi ravi korral väiksem (8–27%) kui platseebo rühmas (40–57%).
The proportion of patients with a reported PR interval prolongation > 200 ms in this study ranged from 3/22 (14%) (day 3) to 8/21 (38%) (day14).
Patsientide protsent, kellel antud uuringus kirjeldati PR-intervalli pikenemist > 200 ms, jäi vahemikku 3/22 (14%) (3. päev) kuni 8/21 (38%) (14. päev).
The proportion of patients with a tumour response (CR, CRu, PR) was significantly higher (p< 0.0001 Chi-Square test) in the R-CVP group (80.9 %) than the CVP group (57.2 %).
Ravile allunud tuumoriga (CR, CRu, PR) patsientide osakaal oli oluliselt suurem (p < 0,0001 hii-ruut-test) R-CVP grupis (80,9 %) kui CVP grupis (57,2 %).
The proportion of patients with ACR 20/50/70 (responses in Studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3) for apremilast 30 mg twice daily at Week 16 are shown in Table 3.
30 mg kaks korda ööpäevas ravitud patsientide osakaal, kellel 16. nädalaks saavutati ACR 20/50/70 ravivastus (uuringud PALACE 1, PALACE 2 ja PALACE 3 ning uuringute PALACE 1, PALACE 2 ja PALACE 3 koondandmed), on esitatud tabelis 3.
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the prucalopride (25.1%) and placebo (20.7%) treatment groups.
Patsientide osakaal, kellel oli 24-nädalases topeltpimedas ravifaasis nädalas keskmiselt ≥ 3 spontaanset täielikku sooletühjendamist, ei olnud prukalopriidi (25,1%) ja platseebo (20,7%) ravirühmas statistiliselt erinev (p = 0,367).
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the Resolor (25.1%) and placebo (20.7%) treatment groups.
Patsientide osakaal, kellel oli 24-nädalases topeltpimedas ravifaasis nädalas keskmiselt ≥ 3 spontaanset täielikku sooletühjendamist, ei olnud Resolori (25,1%) ja platseebo (20,7%) ravirühmas statistiliselt erinev (p = 0,367).
The proportion of patients with at least 15 letters improvement from baseline BCVA in the study eye at week 8 was more than 6-fold higher with OZURDEX (42.9%) compared to
Nende patsientide osakaal, kelle uuritavas silmas paranes nägemisteravus uuringu alguse BSVA-ga võrreldes vähemalt 15 tähe võrra, oli 8. nädalal OZURDEXi rühmas (42,9%) 6-kordselt suurem, võrreldes simuleeritud süstiga (6,6%), p < 0,001.
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8 % in the zoledronic acid-treated group versus 49.6 % in the placebo group (p=0.003).
Vähemalt üks LST (välja arvatud hüperkaltseemia) esines 29,8% zoledroonhappe grupis võrrelduna 49,6% platseebogrupis (p=0,003).
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid -treated group versus 49.6% in the placebo group (p=0.003).
Vähemalt üks LST (välja arvatud hüperkaltseemia) esines 29,8%-l uuritavatest zoledroonhappe grupis võrrelduna 49,6% platseebogrupis (p=0,003).
The proportion of patients with CMV viraemia/syndrome was 13.5 %.
CMV- vireemia/sündroomiga patsientide hulk oli 13,5 %.
The proportion of patients with detectable talimogene laherparepvec DNA in blood and urine was highest during the second cycle.
Patsientide osakaal, kellel veres ja uriinis tuvastati talimogeenlaherparepvek’i DNA, oli kõrgeim teise ravikuuri ajal.
The proportion of patients with improvement in WHO functional class by week 16 was similar in the tadalafil 40 mg and placebo groups (23 % vs.
16ndaks nädalaks WHO funktsionaalse klassi paranemisega patsientide proportsioon oli sarnane tadalafiili 40 mg ja platseebogrupis (23 % vs.
The proportion of patients with infections in C0168T72 was similar to that in the paediatric Crohn’s disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT 1 and ACT 2).
Infektsiooniga patsientide osakaal uuringus C0168T72 oli sarnane Crohni tõvega laste REACH-uuringu omaga, aga suurem kui haavandilise koliidiga täiskasvanute uuringutes (ACT 1 ja ACT 2).
The proportion of patients with pain palliation was statistically significantly higher in the ZYTIGA group than in the placebo group (44% vs.
Leevenenud valuga patsientide osakaal oli statistiliselt olulisel määral suurem ZYTIGA’ga ravitud patsientide rühmas võrreldes platseeborühmaga (44% vs.
The proportion of patients without emesis during 0-72 hours post-operatively was similar after palonosetron 1 µg/kg or 3 µg/kg (88% vs 84%).
Oksendamiseta patsientide osakaal 0–72 tunni vältel pärast operatsiooni oli pärast 1 µg/kg või 3 µg/kg palonosetrooni manustamist sarnane (88% vs 84%).
The proportion of responders in the IKERVIS group was 28.6%, compared to 23.1% in the vehicle group.
IKERVIS’e rühmas oli ravivastuse saavutanud patsientide osakaal 28,6% võrreldes 23,1%-ga vehiikli rühmas.
The proportion of subjects reaching anti-HBs ≥ 10mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix given alone.
Anti-HBs ≥10 mIU/ml saavutanud isikute osakaal oli vaktsiinide koosmanustamise korral 98,3% ja ainult Twinrix’i manustamise korral 100%.
The proportion of subjects reaching anti-HBs  10 mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix alone.
Isikute proportsioon, kellel anti-HBs saavutas  10 mIU/ml oli 98,3% samaaegsel vaktsineerimisel ja 100% ainult Twinrix’i manustamisel.
The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL,
Podagrahoo ravi vajavate uuringus osalejate osakaal (uuringud APEX ja FACT) oli arvuliselt väiksem rühmades, kus saavutati pärast ravi algust keskmine seerumi uraaditase <6,0 mg/dl, <5,0 mg/dl või
The proportion of subjects with a confirmed PSA response was greater in the ZYTIGA group than in the placebo group (62% vs.
Kinnitatud PSA vastusega osalejate osakaal oli suurem ZYTIGA rühmas kui platseeborühmas (62% vs.
The proportion of subjects with clinically significant weight gain (≥ 7 % weight gain from baseline at Day 21) was 14.1 % for asenapine 2.5 mg twice daily, 8.9 % for asenapine 5 mg twice daily, and 9.2 % for asenapine 10 mg twice daily, compared to 1.1 % for placebo.
Kliiniliselt olulise kehakaalu suurenemisega (≥ 7% kehakaalu suurenemine 21. ravipäevaks võrreldes esialgsega) uuritavaid oli 14,1% 2,5 mg asenapiini kaks korda ööpäevas võtnutel, 8,9% 5 mg asenapiini kaks korda ööpäevas võtnutel ja 9,2% 10 mg asenapiini kaks korda ööpäevas võtnutel võrreldes 1,1%-ga platseebot võtnutel.
The proportion of subjects with HIV-1 RNA < 50 copies/mL at week 48 (TLOVR) was 72.2% (26/36).
Isikute osakaal, kelle HIV-1 RNA oli 48. nädalaks < 50 koopiat/ml (TLOVR), oli 72,2% (26/36).
The proportion of subjects with hSBA ≥ 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically superior for serogroups A and Y (Table 10).
Isikute, kelle hSBA oli ≥ 1:8, osakaal oli samaväärne ACWY-PSga kõigis neljas serogrupis ja statistiliselt suurem serogruppides A ja Y (tabel 10).
The proportion of virological failures was 22.2% (8/36).
Viroloogilise ebaõnnestumise osakaal oli 22,2% (8/36).
The proportion was significantly larger than observed with insulin degludec (40.9%, odds ratio 2.28, p < 0.0001) and similar to that observed with liraglutide (57.7%, odds ratio 1.13, p=0.3184).
See osakaal oli oluliselt suurem, kui degludek- insuliini saanud patsientidel (40,9%, riskisuhe 2,28; p < 0,0001) ja sarnane liraglutiidi saanud patsientidele (57,7%, riskisuhe 1,13; p=0,3184).
The proportions of MabThera treated patients showing a minimal clinically important difference (MCID) in HAQ-DI (defined as an individual total score decrease of >0.22) was also higher than among patients receiving methotrexate alone (Table 12).
MabThera’ga ravitud patsientide protsent, kes saavutas HAQ-DI minimaalse kliiniliselt olulise erinevuse (MCID, defineeriti kui individuaalse koguskoori vähenemist >0,22), olid samuti suurem kui ainult metotreksaati saanud patsientide seas (tabel 12).
The proportions of patients in sustained response and sustained remission at week 54 were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% vs.
Püsiva ravivastusega ning püsiva remissiooniga patsientide hulk 54-ndaks nädalaks oli suurem kombineeritud infliksimabi ravirühmas kui platseebo ravirühmas (vastavalt 37,9% vs.
The proportions of patients requiring hospitalisation for respiratory events were 24.4% with TOBI Podhaler and 22.0% with TOBI nebuliser solution.
Hingamisteedega seotud sündmuste tõttu vajas hospitaliseerimist 24,4% TOBI Podhaler’iga ja 22,0% TOBI nebuliseeritava lahusega ravi saanud patsientidest.
The proportions of patients taking placebo who achieved this goal were 28% and 26% respectively.
Platseeboga olid samad näitajad 28% ja 26%.
The proportions of patients with no signs of viral activity in their blood at follow-up were 32% with Pegasys and 22% with lamivudine in the HBeAg-positive patients, and 43% with Pegasys and 29% with lamivudine in the HBeAg-negative patients.
HBeAg-positiivseid patsiente, kellel järelkontrollis puudusid veres viiruse aktiivsuse nähud, oli Pegasysi rühmas 32% ja lamivudiini rühmas 22% ning viiruse aktiivsuse nähtudeta HBeAg-negatiivseid patsiente oli Pegasysi rühmas 43% ja lamivudiini rühmas 29%.
The proportions of subjects with PedACR50/70/90 at Week 12 and Week 24 were 90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively.
PedACR50/70/90 ravivastused 12. ja 24. nädalal olid vastavalt 90,3% / 61,3% / 38,7% ja 83,3% / 73,3% / 36,7%.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
Prospektiivne randomiseeritud uuring (UKPDS) on näidanud vere glükoosisisalduse intensiivse jälgimise pikaajalist kasu 2. tüüpi suhkurtõve korral.
The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the long- term benefit of intensive blood glucose control in type 2 diabetes.
Prospektiivses randomiseeritud uuringus UKPDS (UK Prospective Diabetes Study) leidis tõestust efektiivse veresuhkru kontrolli pikaajaline kasu II tüüpi diabeedi korral.
The protection against influenza lasts only as long as Tamiflu is administered.
Kaitse gripi eest on tagatud vaid senikaua, kuni manustatakse Tamiflu’d.
The protection given by Ibraxion was measured by the reduction of clinical signs of IBR after the virus was introduced to the cattle.
Ibraxioni poolt pakutavat kaitset mõõdeti IBR viirusest põhjustatud kliiniliste nähtude vähenemise kaudu pärast veiste nakatamist viirusega.
The protective cap is removed from the injection needle and air is expelled from the syringe and needle by holding the syringe vertically and gently pressing the plunger upwards.
Eemaldage kaitsekork nõelalt ja suruge õhk süstlast välja hoides süstalt vertikaalselt ja õrnalt pressides ülespoole.
The protective efficacy of a dose of hepatitis B immunoglobulin at birth followed by 3 doses of a previous formulation of Merck’s recombinant hepatitis B vaccine has been demonstrated for neonates born to mothers positive for both hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg).
Vahetult pärast sündi manustatud hepatiit B immuunglobuliini annuse ja sellele järgneva Mercki eelmise rekombinantse hepatiit B vaktsiini 3 annuse kaitse efektiivsust on demonstreeritud vastsündinutel, kelle emad olid nii HBsAg- (hepatiit B viiruse pinnaantigeen) kui ka HBe Ag- (hepatiit B viiruse ümbrise antigeen) positiivsed.
The protective efficacy of the components of PROCOMVAX has been established in field trials performed with the monovalent vaccines.
PROCOMVAX’i komponentide efektiivsus on kindlaks tehtud monovalentsete vaktsiinidega läbiviidud uuringutes.
The protective efficacy of VEPACEL against morbidity and mortality induced by the infection with lethal doses of highly pathogenic avian influenza H5N1 virus was assessed non-clinically in a ferret challenge model.
VEPACEL’i efektiivset kaitset patogeense linnugripi viiruse tüve H5N1 letaalsete annustega esile kutsutud haigestumise ja suremuse vastu hinnati mittekliiniliselt tuhkrute mudelkatses.
The protective vaccine efficacy (pooled doses) observed against any and severe rotavirus gastro-enteritis is presented in the following table:
Vaktsiini kaitseefektiivsus (kõik annused kokku) rotaviirusest tingitud iga raskusastmega ja raske gastroenteriidi vastu on esitatud alljärgnevas tabelis:
The protective vaccine efficacy (pooled doses) observed against any and severe rotavirus gastro-enteritis is presented in the following table:
Vaktsiini kaitsetõhusus (kõik annused kokku) rotaviirusest tingitud igasuguse kuluga ja raske gastroenteriidi vastu on esitatud alljärgnevas tabelis:
The protective vaccine efficacy after two doses of Rotarix observed against severe rotavirus gastro- enteritis up to 2 years of age is presented in the following table:
Vaktsiini kaitsev efektiivsus pärast Rotarixi kahe annuse manustamist raskete rotaviiruslike gastroenteriitide vastu kuni 2aastastel lastel on esitatud alljärgnevas tabelis: